Beijing Beilu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
August 19, 2021 at 06:48 am EDT
Share
Beijing Beilu Pharmaceutical Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 535.275 million compared to CNY 367.617 million a year ago. Operating income was CNY 127.216 million compared to CNY 99.264 million a year ago. Net income was CNY 116.476 million compared to CNY 91.563 million a year ago. Basic earnings per share from continuing operations was CNY 0.24 compared to CNY 0.19 a year ago. Diluted earnings per share from continuing operations was CNY 0.25 compared to CNY 0.19 a year ago.
Beijing Beilu Pharmaceutical Co., Ltd is a China-based company principally engaged in the research, development, production and distribution of contract medium products, anti-diabetic products and anti-anxiety products. The Companyâs main products include gadopentetate dimeglumine injection, iohexol injection, Iodoparol injection, Iodixanol injection, ferric ammonium citrate effervescent granules, repaglinide tablets, glimepiride tablets, Jiuwei Zhenxin granules, among others. The Company mainly distributes its products in domestic market.